<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109373">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02053064</url>
  </required_header>
  <id_info>
    <org_study_id>P2-SAF-301</org_study_id>
    <nct_id>NCT02053064</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up of Sanfilippo Type A Patients Treated by Intracerebral SAF-301 Gene Therapy</brief_title>
  <official_title>Long-term Follow-up of Patients With Sanfilippo Type A Syndrome Who Have Previously Been Treated in the P1-SAF-301 Clinical Study Evaluating the Tolerability and Safety of the Intracerebral Administration of SAF-301.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LYSOGENE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LYSOGENE</source>
  <oversight_info>
    <authority>France: ANSM - Agence National de Sécurité du Médicament</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      P2-SAF-301 is an open-label interventional study without administration of investigational
      product, evaluating the long-term safety and tolerability of intracerebral SAF-301
      previously administered to 4 patients with Sanfilippo type A syndrome.

      The primary objective is to collect additional safety and tolerability data on intracerebral
      SAF-301 previously administered to 4 patients with Sanfilippo type A syndrome.

      The secondary objective is to further collect data to assess the effects of SAF-301 on
      neurological and psychological status, and potential biological markers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Checking of adverse events</measure>
    <time_frame>until 32 months after SAF-301 administration</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Information on neurological and cognitive changes based on clinical status, standardized neurocognitive and behavioral assessments</measure>
    <time_frame>2 years after the injection of SAF-301</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Information on changes in potential biomarkers of the disease</measure>
    <time_frame>2 years after the injection of SAF-301</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Information to further evaluation of immune response</measure>
    <time_frame>2 years after the injection of SAF-301</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Mucopolysaccharidosis Type III A</condition>
  <condition>Sanfilippo Disease Type A</condition>
  <arm_group>
    <arm_group_label>SAF-301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SAF-301</intervention_name>
    <arm_group_label>SAF-301</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having completed the previous phase I/II study (P1-SAF-301),

          -  Family understanding the follow-up procedures and the informed consent,

          -  Patient's parents having signed the informed consent form.

        Exclusion Criteria:

          -  Participation in any other clinical trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kumaran DEIVA, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Hôpital Bicêtre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Paris Sud (Bicêtre)</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 31, 2014</lastchanged_date>
  <firstreceived_date>January 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurodegenerative diseases</keyword>
  <keyword>Nervous systems diseases</keyword>
  <keyword>Genetic diseases, Inborn</keyword>
  <keyword>Metabolic diseases</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Adeno Associated Virus (AAV)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis III</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
